Know Cancer

or
forgot password

A Phase II Study of Combination Chemotherapy With Bevacizumab, Capecitabine and Oxaliplatin in Patients With Previously Untreated Metastatic or Recurrent Colorectal Cancer


Phase 2
18 Years
70 Years
Not Enrolling
Both
Metastatic Colorectal Cancer

Thank you

Trial Information

A Phase II Study of Combination Chemotherapy With Bevacizumab, Capecitabine and Oxaliplatin in Patients With Previously Untreated Metastatic or Recurrent Colorectal Cancer


Inclusion Criteria:



- Histologically or cytologically documented colorectal adenocarcinoma

- ECOG performance status of 2 or lower

- Adequate bone marrow function

- Adequate kidney function

- Adequate liver function

- Informed consent

Exclusion Criteria:

- Major surgical procedure or significant traumatic injury within 28 days prior to
study treatment start

- Known allergy to study drugs

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

time to progression

Outcome Time Frame:

6 months

Safety Issue:

No

Principal Investigator

Tae Won Kim, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Asan Medical Center

Authority:

Korea: Food and Drug Administration

Study ID:

AMC-ONCGI-0277

NCT ID:

NCT00378066

Start Date:

August 2006

Completion Date:

October 2008

Related Keywords:

  • Metastatic Colorectal Cancer
  • Colorectal Neoplasms

Name

Location